Session

Back to Programme Overview

Testicular cancer - new approaches in surgery and systemic treatment

Poster Session 82

  • Location:
    Room Paris, North Hall (Level 1)
  • Chairs:
     M. Jewett, Toronto (CA)
     D.L. Nicol, London (GB)
     N. Nicolai, Milan (IT)
  • Aims and objectives of this session

    This session will update the audience with new indications and outcome results from surgical approaches together with new systemic treatment options for patients with advanced germ cell cancer. In addition, quality of care issues will be discussed based on large registries.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
1084
Non-guideline concordant treatment of testicular cancer

By: Paffenholz P., Pfister D., Heidenreich A.

Institutes: University Hospital Cologne, Dept. of Urology, Cologne, Germany

* 1085
Testicular cancer in patients with learning disabilities in England from 2001-2015: A national cohort study

By: Afshar M.2, Jackson-Spence F.1, De Santis M.3, Tanner J-R.4, Evison F.5, James N.3, Selby P.6, Patel P.7

Institutes: 1University of Birmingham, Medical School, Birmingham, United Kingdom, 2St George’s University Hospitals NHS Foundation Trust, Dept. of Urological Oncology, London, United Kingdom, 3University of Warwick, Cancer Research Unit, Coventry, United Kingdom, 4University Hospitals Birmingham NHS Foundation Trust, Dept. of Oncology, Birmingham, United Kingdom, 5University Hospitals Birmingham NHS Foundation Trust, Dept. of Informatics, Birmingham, United Kingdom, 6University of Leeds, Leeds Institute of Cancer & Pathology, Leeds, United Kingdom, 7University of Birmingham, School of Cancer Sciences, Birmingham, United Kingdom

1086
Reliability of frozen section examination in a large cohort of testicular masses: What did we learn?

By: Vartolomei M.D.1, Matei D.V.2, Renne G.3, Tringali V.M.2, Ferro M.2, Bianchi R.2, Russo A.2, Cozzi G.2, De Cobelli O.4

Institutes: 1University of Medicine and Pharmacy, Targu Mures, Romania and European Institute of Oncology, Dept. of Cell and Molecular Biology and Dept. of Urology, Milan, Italy, 2European Institute of Oncology, Dept. of Urology, Milan, Italy, 3European Institute of Oncology, Dept. of Pathology, Milan, Italy, 4European Institute of Oncology and University of Milan, Dept. of Urology, Milan, Italy

1087
Diagnostic value of frozen section examination (FSE) during inguinal exploration in patients with inconclusive testicular lesions

By: Fankhauser C.1, Beyer J.2, Roth L.1, Sulser T.1, Bode K-P.3, Moch H.3, Hermanns T.1

Institutes: 1University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zurich, University of Zurich, Dept. of Oncology, Zurich, Switzerland, 3University Hospital Zurich, University of Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland

1088
Safety of testicular prosthesis insertion at the time of radical orchiectomy for testis cancer in patients undergoing adjuvant therapies

By: Musi G.1, Cozzi G.1, Bianchi R.1, Mistretta F.A.1, Tringali V.M.L.1, Jereczeck B.A.2, Nolé F.3, De Cobelli O.1

Institutes: 1European Institute of Oncology, Dept. of Urology, Milan, Italy, 2European Institute of Oncology, Dept. of Radiotherapy, Milan, Italy, 3European Institute of Oncology, Dept. of Oncology, Milan, Italy

1089
Laparoscopic retroperitoneal lymph-node dissection (L-RPLND) is not only a staging procedure in stage I non-seminomatous germ-cell testicular tumors (NSGCTT): Mature data from a referral centre

By: Nicolai N.1, Tarabelloni N.2, Catanzaro M.1, Gasperoni F.2, Stagni S.1, Torelli T.1, Tesone A.1, Kungulli A.1, Necchi A.3, Giannatempo P.3, Raggi D.3, Colecchia M.4, Salvioni R.1, Piva L.1, Pizzocaro G.5, Biasoni D.1

Institutes: 1Fondazione Irccs Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy, 2Mox- Politecnico Di Milano, Dept. of Mathematics, Milan, Italy, 3Fondazione Irccs Istituto Nazionale Tumori, Dept. of Medical Oncology, Milan, Italy, 4Fondazione Irccs Istituto Nazionale Tumori, Dept. of Pathology, Milan, Italy, 5Fondazione Irccs Istituto Nazionale Tumori, Emeritus, Milan, Italy

1090
Primary retroperitoneal lymph node dissection (RPLND) in Stage II A/B seminoma patients without adjuvant treatment: A phase II trial (PRIMETEST)

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

1091
Surgical resection of residual tumours after adjuvant chemotherapy of germ cell (GC) tumour

By: Gonzalez F.1, Bossavy J-P.1, Otal P.2, Quintyn-Rant M-L.3, Roumiguié M.4, Chevreau C.5, Malavaud B.4

Institutes: 1Chu Toulouse Rangueil, Dept. of Vascular Surgery, Toulouse, France, 2Chu Toulouse Rangueil, Dept. of Radiology, Toulouse, France, 3Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, 4Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, 5Institut Universitaire Du Cancer, Dept. of Medical Oncology, Toulouse, France

1092
Complications and adjunctive surgical procedures in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) to define a tertial referral center

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

1093
Bone metastases in germ cell tumours: Surgical management and outcomes

By: Nini A.1, Konieczny M.2, Winter C.3, Lusch A.3, Krauspe R.2, Albers P.3

Institutes: 1, IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Orthopedic Surgery, Düsseldorf, Germany, 3University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Urology, Düsseldorf, Germany

1094
Retinal toxicity after cisplatin-based chemotherapy in patients with testicular cancer

By: Gild P.1, Vetterlein M.1, Dieckmann K.P.2, Matthies C.3, Wagner W.3, Ludwig T.1, Meyer C.1, Soave A.1, Dulz S.4, Asselborn N.4, Oechsle K.5, Bokemeyer C.5, Becker A.1, Fisch M.1, Hartmann M.1, Chun F.1, Kluth L.A.1

Institutes: 1University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2Albertinen Hospital, Dept. of Urology, Hamburg, Germany, 3Bundeswehr Medical Center Hamburg, Dept. of Urology, Hamburg, Germany, 4University Medical Center Hamburg-Eppendorf, Dept. of Ophthalmology, Hamburg, Germany, 5University Medical Center Hamburg-Eppendorf, Dept. of Medical Oncology, Hamburg, Germany

1095
The features and management of late relapse of non-seminomatous germ cell tumours

By: Jay A., Aldiwani M., Wijayarathna S., Huddart R., Mayer E., Nicol D.

Institutes: Royal Marsden Hospital, Dept. of Urology, Chelsea, United Kingdom

1096
Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database

By: Necchi A.1, Rosti G.2, Badoglio M.3, Giannatempo P.4, Secondino S.2, Lanza F.5, Pedrazzoli P.2

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS Policlinico San Matteo, Dept. of Medical Oncology, Pavia, Italy, 3EBMT, EBMT Study Offices, Paris, France, 4Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 5Hospital of Ravenna, Dept. of Hematology, Ravenna, Italy

1097
Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial

By: Necchi A.1, Lo Vullo S.2, Giannatempo P.1, Raggi D.1, Calareso G.3, Togliardi E.4, Crippa F.5, Pennati M.6, Zaffaroni N.6, Perrone F.7, Colecchia M.7, Nicolai N.8, Mariani L.2, Salvioni R.8

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Nuclear Medicine – PET Unit, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy, 7Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, 8Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy

Final comments
 N. Nicolai, Milan (IT)